Ventyx Biosciences, Inc. (NASDAQ:VTYX) Director Sheila Gujrathi Acquires 130,000 Shares

Ventyx Biosciences, Inc. (NASDAQ:VTYX) Director Sheila Gujrathi bought 130,000 shares of the company’s stock in a transaction dated Monday, December 23rd. The stock was bought at an average cost of $2.31 per share, with a total value of $300,300.00. Following the completion of the transaction, the director now owns 130,000 shares in the company, valued at approximately $300,300. This trade represents a ∞ increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Ventyx Biosciences Stock Performance

Shares of VTYX opened at $2.38 on Friday. The firm’s 50-day simple moving average is $2.29 and its two-hundred day simple moving average is $2.32. Ventyx Biosciences, Inc. has a fifty-two week low of $1.67 and a fifty-two week high of $11.48. The stock has a market cap of $168.29 million, a PE ratio of -1.01 and a beta of 0.48.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on VTYX shares. Oppenheimer reissued an “outperform” rating and issued a $9.00 price target (down from $10.00) on shares of Ventyx Biosciences in a research note on Friday, November 8th. HC Wainwright restated a “neutral” rating and issued a $6.00 target price on shares of Ventyx Biosciences in a research note on Monday, November 11th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $10.00.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. JPMorgan Chase & Co. boosted its holdings in Ventyx Biosciences by 2.0% in the third quarter. JPMorgan Chase & Co. now owns 1,007,519 shares of the company’s stock worth $2,196,000 after acquiring an additional 20,236 shares in the last quarter. Barclays PLC raised its position in shares of Ventyx Biosciences by 273.1% in the 3rd quarter. Barclays PLC now owns 80,295 shares of the company’s stock worth $175,000 after purchasing an additional 58,776 shares during the last quarter. Geode Capital Management LLC boosted its stake in Ventyx Biosciences by 5.9% in the 3rd quarter. Geode Capital Management LLC now owns 1,391,702 shares of the company’s stock worth $3,034,000 after purchasing an additional 77,350 shares in the last quarter. XTX Topco Ltd purchased a new stake in Ventyx Biosciences during the 3rd quarter valued at about $246,000. Finally, State Street Corp increased its stake in Ventyx Biosciences by 0.8% during the 3rd quarter. State Street Corp now owns 1,187,650 shares of the company’s stock valued at $2,589,000 after purchasing an additional 9,783 shares in the last quarter. Institutional investors own 97.88% of the company’s stock.

About Ventyx Biosciences

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease.